Terms: = Ovarian cancer AND CARS, P49589, 833, ENSG00000110619 AND Treatment
36 results:
1. Nanoscale CAR Organization at the Immune Synapse Correlates with CAR-T Effector Functions.
Sajman J; Yakovian O; Unger Deshet N; Almog S; Horn G; Waks T; Globerson Levin A; Sherman E
Cells; 2023 Sep; 12(18):. PubMed ID: 37759484
[TBL] [Abstract] [Full Text] [Related]
2. Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Ranoa DRE; Sharma P; Schane CP; Lewis AN; Valdez E; Marada VVVR; Hager MV; Montgomery W; Wolf SP; Schreiber K; Schreiber H; Bailey K; Fan TM; Hergenrother PJ; Roy EJ; Kranz DM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37258040
[TBL] [Abstract] [Full Text] [Related]
3. Clinical Activity of Olvimulogene Nanivacirepvec-Primed Immunochemotherapy in Heavily Pretreated Patients With Platinum-Resistant or Platinum-Refractory ovarian cancer: The Nonrandomized Phase 2 VIRO-15 Clinical Trial.
Holloway RW; Mendivil AA; Kendrick JE; Abaid LN; Brown JV; LeBlanc J; McKenzie ND; Mori KM; Ahmad S
JAMA Oncol; 2023 Jul; 9(7):903-908. PubMed ID: 37227734
[TBL] [Abstract] [Full Text] [Related]
4. Chimeric Antigen Receptor T-cell Therapy in cancer: A Critical Review.
Sharma R; Suravarjhula L; Banerjee M; Kumar G; Kumar N
Curr Drug Res Rev; 2023; 15(3):241-261. PubMed ID: 36825696
[TBL] [Abstract] [Full Text] [Related]
5. Integrated multi-omic analysis of low-grade ovarian serous carcinoma collected from short and long-term survivors.
Wong KK; Bateman NW; Ng CW; Tsang YTM; Sun CS; Celestino J; Nguyen TV; Malpica A; Hillman RT; Zhang J; Futreal PA; Rojas C; Conrads KA; Hood BL; Dalgard CL; Wilkerson MD; Phippen NT; Conrads TP; Maxwell GL; Sood AK; Gershenson DM
J Transl Med; 2022 Dec; 20(1):606. PubMed ID: 36528667
[TBL] [Abstract] [Full Text] [Related]
6. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
Matsuzaki J; Lele S; Odunsi K; Tsuji T
Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
[TBL] [Abstract] [Full Text] [Related]
7. Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities.
Xu Y; Jiang J; Wang Y; Wang W; Li H; Lai W; Zhou Z; Zhu W; Xiang Z; Wang Z; Zhu Z; Yu L; Huang X; Zheng H; Wu S
Front Immunol; 2021; 12():725330. PubMed ID: 34386017
[TBL] [Abstract] [Full Text] [Related]
8. Chimeric Antigen Receptor Design and Efficacy in ovarian cancer treatment.
Terlikowska KM; Dobrzycka B; Terlikowski SJ
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33800608
[TBL] [Abstract] [Full Text] [Related]
9. Preclinical Activity of Embryonic Annexin A2-Specific Chimeric Antigen Receptor T Cells Against ovarian cancer.
Leong L; Tan HL; Cua S; Yong KSM; Chen Q; Choo A
Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31936170
[TBL] [Abstract] [Full Text] [Related]
10. CXCR1- or CXCR2-modified CAR T cells co-opt IL-8 for maximal antitumor efficacy in solid tumors.
Jin L; Tao H; Karachi A; Long Y; Hou AY; Na M; Dyson KA; Grippin AJ; Deleyrolle LP; Zhang W; Rajon DA; Wang QJ; Yang JC; Kresak JL; Sayour EJ; Rahman M; Bova FJ; Lin Z; Mitchell DA; Huang J
Nat Commun; 2019 Sep; 10(1):4016. PubMed ID: 31488817
[TBL] [Abstract] [Full Text] [Related]
11. Sexual Dysfunction in Survivorship; the Impact of Menopause and Endocrine Therapy.
Kuehn R; Casaubon J; Raker C; Edmonson D; Stuckey A; Gass J
Ann Surg Oncol; 2019 Oct; 26(10):3159-3165. PubMed ID: 31342358
[TBL] [Abstract] [Full Text] [Related]
12. Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Oza AM; Matulonis UA; Malander S; Hudgens S; Sehouli J; Del Campo JM; Berton-Rigaud D; Banerjee S; Scambia G; Berek JS; Lund B; Tinker AV; Hilpert F; Vázquez IP; D'Hondt V; Benigno B; Provencher D; Buscema J; Agarwal S; Mirza MR
Lancet Oncol; 2018 Aug; 19(8):1117-1125. PubMed ID: 30026000
[TBL] [Abstract] [Full Text] [Related]
13. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells.
Han Y; Xie W; Song DG; Powell DJ
J Hematol Oncol; 2018 Jul; 11(1):92. PubMed ID: 29980239
[TBL] [Abstract] [Full Text] [Related]
14. Chemical Analysis of Morphological Changes in Lysophosphatidic Acid-Treated ovarian cancer Cells.
Bailey KA; Klymenko Y; Feist PE; Hummon AB; Stack MS; Schultz ZD
Sci Rep; 2017 Nov; 7(1):15295. PubMed ID: 29127342
[TBL] [Abstract] [Full Text] [Related]
15. National cancer Database Report of Lymphadenectomy Trends in Endometrial cancer.
Cripe J; Handorf E; Brown J; Jain A; Rubin S; Mantia-Smaldone G
Int J Gynecol Cancer; 2017 Sep; 27(7):1408-1415. PubMed ID: 28525495
[TBL] [Abstract] [Full Text] [Related]
16. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.
Ang WX; Li Z; Chi Z; Du SH; Chen C; Tay JC; Toh HC; Connolly JE; Xu XH; Wang S
Oncotarget; 2017 Feb; 8(8):13545-13559. PubMed ID: 28088790
[TBL] [Abstract] [Full Text] [Related]
17. Tumor Regression and Delayed Onset Toxicity Following B7-H4 CAR T Cell Therapy.
Smith JB; Lanitis E; Dangaj D; Buza E; Poussin M; Stashwick C; Scholler N; Powell DJ
Mol Ther; 2016 Nov; 24(11):1987-1999. PubMed ID: 27439899
[TBL] [Abstract] [Full Text] [Related]
18. Outcomes Following Interval Debulking Surgery in Primary Peritoneal Carcinoma.
Connolly CF; Yahya S; Chan KK; Singh K; Sundar S; Anwar SM; Fernando I
Anticancer Res; 2016 Jan; 36(1):255-9. PubMed ID: 26722051
[TBL] [Abstract] [Full Text] [Related]
19. Outcomes of ovarian stimulation after treatment with chemotherapy.
Chan JL; Johnson LN; Efymow BL; Sammel MD; Gracia CR
J Assist Reprod Genet; 2015 Oct; 32(10):1537-45. PubMed ID: 26400507
[TBL] [Abstract] [Full Text] [Related]
20. Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
Schutsky K; Song DG; Lynn R; Smith JB; Poussin M; Figini M; Zhao Y; Powell DJ
Oncotarget; 2015 Oct; 6(30):28911-28. PubMed ID: 26359629
[TBL] [Abstract] [Full Text] [Related]
[Next]